AMAG 34.91 Amag Pharmaceuticals $AMAG Hit a 52 week high of 35.43 Closing the day 11/10/14 at 34.91 -0.04 -0.11% With a day low of 34.50 and a total volume of 193,339.
AMAG Recent Posts: http://investorshangout.com/AMAG-Pharmaceutic...MAG-53294/
AMAG Amag Pharmaceuticals Recent Headline News
Repros Soars on Positive FDA Meeting Regarding Androxa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 4:20PM CST
Shares of Repros Therapeutics (RPRX) shot up 56.9% following a successful meeting with the FDA regarding Androxal.
BIIB: 327.87 (+7.12), RPRX: 9.22 (-0.90), ABBV: 63.79 (+2.29), AMAG: 34.91 (-0.04)
Theravance Biopharma Q3 Loss Widens Y/Y, Revenues Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 10:20AM CST
Theravance Biopharma reported a third-quarter 2014 loss of $1.72 per share.
AMAG: 34.91 (-0.04), TBPH: 18.32 (+1.25), GSK: 45.16 (+0.25), THRX: 13.44 (-0.83)
BIND Therapeutics (BIND) Worth a Look: Stock Rises 5.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 7:30AM CST
BIND Therapeutics, Inc. (BIND) was a big mover last session, as the company saw its shares rise over 5% on the day.
AGEN: 3.04 (+0.02), AMAG: 34.91 (-0.04), BIND: 9.64 (+0.42), AFFX: 9.42 (-0.01)
Keryx (KERX) in Focus: Stock Adds 11.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 8:46AM CST
Keryx (KERX) was a big mover last session, with shares rising nearly 12% on the day.
AGEN: 3.04 (+0.02), BIIB: 327.87 (+7.12), AMAG: 34.91 (-0.04), KERX: 16.43 (-0.30)
VIVUS Posts Narrower-than-Expected Q3 Loss, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 3:45PM CST
VIVUS Inc.'s (VVUS) third-quarter 2014 loss of 11 cents per share was much narrower than the Zacks Consensus Estimate of a loss of 21 cents.
AUXL: 32.70 (-0.05), VVUS: 3.23 (-0.10), AMAG: 34.91 (-0.04), SNY: 46.19 (+0.50)
Myriad Genetics Down on Earnings, Revenue Miss in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 2:30PM CST
Myriad Genetics (MYGN) believes the current trajectory of its Hereditary Cancer franchise puts it in a better position to achieve increased profitability and reach its targeted goals.
AGEN: 3.04 (+0.02), MYGN: 32.80 (-2.09), AMAG: 34.91 (-0.04), AFFX: 9.42 (-0.01)
Celldex Falls with Pipeline Update Overshadowing Q3 Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 1:57PM CST
Celldex Therapeutics, Inc. (CLDX) amended the protocol for a pivotal study being conducted on glembatumumab vedotin for the treatment of triple negative breast cancer.
BIIB: 327.87 (+7.12), ANIP: 48.21 (+2.21), CLDX: 14.81 (+1.39), AMAG: 34.91 (-0.04)
Genomic Health Q3 Loss Narrower than Expected, Revenues Lag - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 1:50PM CST
In the third quarter of 2014, Genomic Health (GHDX) expanded Medicaid coverage for the Oncotype DX breast cancer test, extending coverage to more than 40 million Medicaid patients in 35 states .
AGEN: 3.04 (+0.02), AMAG: 34.91 (-0.04), GHDX: 36.20 (+0.39), AFFX: 9.42 (-0.01)
Alnylam's Q3 Loss Narrower than Expected, Pipeline in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 11:40AM CST
Alnylam (ALNY) reported third-quarter 2014 loss of 58 cents per share, much wider than the year-ago loss of 48 cents per share.
BIIB: 327.87 (+7.12), ALNY: 99.18 (+3.34), AMAG: 34.91 (-0.04)
Celldex (CLDX) in Focus: Stock Tanks 21% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 7:50AM CST
Celldex has been witnessing a flat trend in its current year loss estimates and its share price has been falling for past few days
AGEN: 3.04 (+0.02), CLDX: 14.81 (+1.39), AMAG: 34.91 (-0.04), AFFX: 9.42 (-0.01)
Jazz Pharmaceuticals Q3 Earnings Rise Y/Y, Lifts Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 1:20PM CST
Jazz Pharmaceuticals' (JAZZ) third-quarter 2014 adjusted earnings of $2.07 per share were above the year-ago adjusted earnings.
BIIB: 327.87 (+7.12), JAZZ: 174.43 (+3.63), AMAG: 34.91 (-0.04)
Pharmacyclics Tops Q3 Earnings, Ties Up with AstraZeneca - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 11:00AM CST
Pharmacyclics, Inc. (PCYC) reported third-quarter 2014 earnings (including stock-based compensation expenses) of 53 cents per share, above the Zacks Consensus Estimate of 45 cents.
JNJ: 108.82 (+0.62), PCYC: 133.98 (+0.49), AZN: 73.21 (+0.33), AMAG: 34.91 (-0.04)
Cytokinetics, Incorporated (CYTK) in Focus: Stock Surges 16.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 8:18AM CST
Cytokinetics, Incorporated (CYTK) was a big mover last session, as the company saw its shares rise by over 16% on the day.
AGEN: 3.04 (+0.02), CYTK: 4.33 (+0.23), AMAG: 34.91 (-0.04), AFFX: 9.42 (-0.01)
Achillion Pharmaceuticals Slumps: ACHN Plunges 15.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 7:34AM CST
Achillion Pharmaceuticals (ACHN) fell nearly 16% in the last trading session amid huge volumes, reversing its recent trend, as the stock is now up nearly 3% in the past one month.
AGEN: 3.04 (+0.02), HSKA: 16.40 (+0.50), ACHN: 12.85 (+2.74), AMAG: 34.91 (-0.04)
Regeneron Q3 Earnings Up Y/Y, Narrows Eylea Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:30PM CST
Regeneron Pharmaceuticals' (REGN) third-quarter 2014 adjusted earnings (including stock-based compensation expense) of $2.23 per share surpassed the Zacks Consensus Estimate.
AMAG: 34.91 (-0.04), SNY: 46.19 (+0.50), REGN: 385.97 (+8.13)
MannKind Falls on Missing Q3 Estimates Yet Cuts Loss Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 11:40AM CST
MannKind's (MNKD) third-quarter 2014 loss came in at 9 cents per share, much narrower than the year-ago loss of 17 cents per share.
BIIB: 327.87 (+7.12), AMAG: 34.91 (-0.04), SNY: 46.19 (+0.50), MNKD: 5.88 (+0.10)
Integra Beats Earnings, Sales Up Y/Y, Outlook Lowered - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 10:20AM CST
Integra's (IART) total revenue during the reported quarter increased 7.7% year over year to $229.7 million, but missed the Zacks Consensus Estimate by 1.4%
AGEN: 3.04 (+0.02), IART: 47.38 (+0.33), AMAG: 34.91 (-0.04), AFFX: 9.42 (-0.01)
AMAG Pharmaceuticals Shares Up 59.1% Since SmarTrend's Buy Recommendation (AMAG)
Comtex SmarTrend(R) - Tue Nov 04, 9:40AM CST
SmarTrend identified an Uptrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on August 11th, 2014 at $20.91. In approximately 3 months, AMAG Pharmaceuticals has returned 59.05% as of today's recent price of $33.25.
AMAG: 34.91 (-0.04)
Arena Pharmaceuticals Posts In Line Q3 Loss, Belviq Grows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 8:30AM CST
Arena Pharmaceuticals (ARNA) reported a net loss of 13 cents per share in the third quarter of 2014 in line with the Zacks Consensus Estimate.
VVUS: 3.23 (-0.10), AMAG: 34.91 (-0.04), ARNA: 4.40 (+0.14)
Theravance (THRX) Falls on Wider-than-Expected Loss in Q3 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 8:10AM CST
Theravance reported third-quarter 2014 loss of 19 cents per share.
AMAG: 34.91 (-0.04), TBPH: 18.32 (+1.25), GSK: 45.16 (+0.25), THRX: 13.44 (-0.83)
AMAG Recent Posts: http://investorshangout.com/AMAG-Pharmaceutic...MAG-53294/
AMAG Amag Pharmaceuticals Recent Headline News
Repros Soars on Positive FDA Meeting Regarding Androxa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 4:20PM CST
Shares of Repros Therapeutics (RPRX) shot up 56.9% following a successful meeting with the FDA regarding Androxal.
BIIB: 327.87 (+7.12), RPRX: 9.22 (-0.90), ABBV: 63.79 (+2.29), AMAG: 34.91 (-0.04)
Theravance Biopharma Q3 Loss Widens Y/Y, Revenues Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 10:20AM CST
Theravance Biopharma reported a third-quarter 2014 loss of $1.72 per share.
AMAG: 34.91 (-0.04), TBPH: 18.32 (+1.25), GSK: 45.16 (+0.25), THRX: 13.44 (-0.83)
BIND Therapeutics (BIND) Worth a Look: Stock Rises 5.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 7:30AM CST
BIND Therapeutics, Inc. (BIND) was a big mover last session, as the company saw its shares rise over 5% on the day.
AGEN: 3.04 (+0.02), AMAG: 34.91 (-0.04), BIND: 9.64 (+0.42), AFFX: 9.42 (-0.01)
Keryx (KERX) in Focus: Stock Adds 11.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 8:46AM CST
Keryx (KERX) was a big mover last session, with shares rising nearly 12% on the day.
AGEN: 3.04 (+0.02), BIIB: 327.87 (+7.12), AMAG: 34.91 (-0.04), KERX: 16.43 (-0.30)
VIVUS Posts Narrower-than-Expected Q3 Loss, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 3:45PM CST
VIVUS Inc.'s (VVUS) third-quarter 2014 loss of 11 cents per share was much narrower than the Zacks Consensus Estimate of a loss of 21 cents.
AUXL: 32.70 (-0.05), VVUS: 3.23 (-0.10), AMAG: 34.91 (-0.04), SNY: 46.19 (+0.50)
Myriad Genetics Down on Earnings, Revenue Miss in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 2:30PM CST
Myriad Genetics (MYGN) believes the current trajectory of its Hereditary Cancer franchise puts it in a better position to achieve increased profitability and reach its targeted goals.
AGEN: 3.04 (+0.02), MYGN: 32.80 (-2.09), AMAG: 34.91 (-0.04), AFFX: 9.42 (-0.01)
Celldex Falls with Pipeline Update Overshadowing Q3 Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 1:57PM CST
Celldex Therapeutics, Inc. (CLDX) amended the protocol for a pivotal study being conducted on glembatumumab vedotin for the treatment of triple negative breast cancer.
BIIB: 327.87 (+7.12), ANIP: 48.21 (+2.21), CLDX: 14.81 (+1.39), AMAG: 34.91 (-0.04)
Genomic Health Q3 Loss Narrower than Expected, Revenues Lag - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 1:50PM CST
In the third quarter of 2014, Genomic Health (GHDX) expanded Medicaid coverage for the Oncotype DX breast cancer test, extending coverage to more than 40 million Medicaid patients in 35 states .
AGEN: 3.04 (+0.02), AMAG: 34.91 (-0.04), GHDX: 36.20 (+0.39), AFFX: 9.42 (-0.01)
Alnylam's Q3 Loss Narrower than Expected, Pipeline in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 11:40AM CST
Alnylam (ALNY) reported third-quarter 2014 loss of 58 cents per share, much wider than the year-ago loss of 48 cents per share.
BIIB: 327.87 (+7.12), ALNY: 99.18 (+3.34), AMAG: 34.91 (-0.04)
Celldex (CLDX) in Focus: Stock Tanks 21% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 7:50AM CST
Celldex has been witnessing a flat trend in its current year loss estimates and its share price has been falling for past few days
AGEN: 3.04 (+0.02), CLDX: 14.81 (+1.39), AMAG: 34.91 (-0.04), AFFX: 9.42 (-0.01)
Jazz Pharmaceuticals Q3 Earnings Rise Y/Y, Lifts Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 1:20PM CST
Jazz Pharmaceuticals' (JAZZ) third-quarter 2014 adjusted earnings of $2.07 per share were above the year-ago adjusted earnings.
BIIB: 327.87 (+7.12), JAZZ: 174.43 (+3.63), AMAG: 34.91 (-0.04)
Pharmacyclics Tops Q3 Earnings, Ties Up with AstraZeneca - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 11:00AM CST
Pharmacyclics, Inc. (PCYC) reported third-quarter 2014 earnings (including stock-based compensation expenses) of 53 cents per share, above the Zacks Consensus Estimate of 45 cents.
JNJ: 108.82 (+0.62), PCYC: 133.98 (+0.49), AZN: 73.21 (+0.33), AMAG: 34.91 (-0.04)
Cytokinetics, Incorporated (CYTK) in Focus: Stock Surges 16.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 8:18AM CST
Cytokinetics, Incorporated (CYTK) was a big mover last session, as the company saw its shares rise by over 16% on the day.
AGEN: 3.04 (+0.02), CYTK: 4.33 (+0.23), AMAG: 34.91 (-0.04), AFFX: 9.42 (-0.01)
Achillion Pharmaceuticals Slumps: ACHN Plunges 15.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 7:34AM CST
Achillion Pharmaceuticals (ACHN) fell nearly 16% in the last trading session amid huge volumes, reversing its recent trend, as the stock is now up nearly 3% in the past one month.
AGEN: 3.04 (+0.02), HSKA: 16.40 (+0.50), ACHN: 12.85 (+2.74), AMAG: 34.91 (-0.04)
Regeneron Q3 Earnings Up Y/Y, Narrows Eylea Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:30PM CST
Regeneron Pharmaceuticals' (REGN) third-quarter 2014 adjusted earnings (including stock-based compensation expense) of $2.23 per share surpassed the Zacks Consensus Estimate.
AMAG: 34.91 (-0.04), SNY: 46.19 (+0.50), REGN: 385.97 (+8.13)
MannKind Falls on Missing Q3 Estimates Yet Cuts Loss Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 11:40AM CST
MannKind's (MNKD) third-quarter 2014 loss came in at 9 cents per share, much narrower than the year-ago loss of 17 cents per share.
BIIB: 327.87 (+7.12), AMAG: 34.91 (-0.04), SNY: 46.19 (+0.50), MNKD: 5.88 (+0.10)
Integra Beats Earnings, Sales Up Y/Y, Outlook Lowered - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 10:20AM CST
Integra's (IART) total revenue during the reported quarter increased 7.7% year over year to $229.7 million, but missed the Zacks Consensus Estimate by 1.4%
AGEN: 3.04 (+0.02), IART: 47.38 (+0.33), AMAG: 34.91 (-0.04), AFFX: 9.42 (-0.01)
AMAG Pharmaceuticals Shares Up 59.1% Since SmarTrend's Buy Recommendation (AMAG)
Comtex SmarTrend(R) - Tue Nov 04, 9:40AM CST
SmarTrend identified an Uptrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on August 11th, 2014 at $20.91. In approximately 3 months, AMAG Pharmaceuticals has returned 59.05% as of today's recent price of $33.25.
AMAG: 34.91 (-0.04)
Arena Pharmaceuticals Posts In Line Q3 Loss, Belviq Grows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 8:30AM CST
Arena Pharmaceuticals (ARNA) reported a net loss of 13 cents per share in the third quarter of 2014 in line with the Zacks Consensus Estimate.
VVUS: 3.23 (-0.10), AMAG: 34.91 (-0.04), ARNA: 4.40 (+0.14)
Theravance (THRX) Falls on Wider-than-Expected Loss in Q3 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 8:10AM CST
Theravance reported third-quarter 2014 loss of 19 cents per share.
AMAG: 34.91 (-0.04), TBPH: 18.32 (+1.25), GSK: 45.16 (+0.25), THRX: 13.44 (-0.83)
